SPRY2 and response to FOLFOX/CAPOX in metastatic KRAS mutated colorectal cancer

被引：0
|
作者：
Montal, R. [1 ]
Merche, M. -V. [1 ]
Anta, B. [2 ]
Martinez, N. [2 ]
Santos, C. [1 ,3 ]
Sanjuan, X. [4 ]
Paules, M. J. [5 ]
Perez Martin, F. J. [6 ]
Azuara, D. [3 ]
Salazar, R. [1 ,3 ]
Rojas, J. M. [2 ]
机构：
[1] Inst Catala Oncol IDIBELL, Dept Med Oncol, Lhospitalet De Llobregat, Spain
[2] Inst Salud Carlos III UFIEC, Majadahonda, Spain
[3] Inst Catala Oncol IDIBELL, Translat Res Lab, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Bellvitge IDIBELL, Dept Pathol, Lhospitalet De Llobregat, Spain
[5] HUB, IDIBELL, Interdisciplinary Comm Esophagogastr Tumours, Lhospitalet De Llobregat, Spain
[6] Inst Catala Oncol ICO LHospitalet, IDIBELL, Clin Res Unit, Lhospitalet De Llobregat, Spain
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
10.1093/annonc/mdv233.193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-195
引用
收藏
页数：1
相关论文
共 50 条
  • [21] FOLFOX resistance in TP53-mutated Metastatic Colorectal Cancer: mechanism and selective targeting
    Hollande, Frederic
    Behrenbruch, Corina
    Foroutan, Momeneh
    Simpson, Kaylene
    Heriot, Alexander
    CANCER SCIENCE, 2023, 114 : 739 - 739
  • [22] Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
    W Chua
    D Goldstein
    C K Lee
    H Dhillon
    M Michael
    P Mitchell
    S J Clarke
    B Iacopetta
    British Journal of Cancer, 2009, 101 : 998 - 1004
  • [23] Sotorasib in KRAS-Mutated Colorectal Cancer
    Fojo, Tito
    Fakih, Marwan G.
    Chao, Joseph
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (02): : 186 - 187
  • [24] Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin
    Nagourney, Robert A.
    Evans, Steven
    Tran, Peter H.
    Nagourney, Adam J.
    Sugarbaker, Paul H.
    EJSO, 2021, 47 (04): : 738 - 742
  • [25] SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma
    Masum Saini
    Aakanksha Verma
    Sam J. Mathew
    Cell Death & Disease, 9
  • [26] SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma
    Saini, Masum
    Verma, Aakanksha
    Mathew, Sam J.
    CELL DEATH & DISEASE, 2018, 9
  • [27] Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
    K-L G Spindler
    N Pallisgaard
    R F Andersen
    A Jakobsen
    British Journal of Cancer, 2014, 111 : 2380 - 2380
  • [28] Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
    Spindler, K-L G.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2380 - 2380
  • [29] Spry2 expression correlates with BRAF mutation in thyroid cancer DISCUSSION
    Shen, Wen Tsong
    Patel, Kepal N.
    Parangi, Sareh
    Kandil, Emad
    SURGERY, 2010, 148 (06) : 1287 - 1287
  • [30] Difference in appearance of KRAS mutated ctDNA in patients with metastatic colorectal cancer during treatments.
    Takayama, Yuji
    Suzuki, Koichi
    Ichida, Kosuke
    Fukui, Taro
    Watanabe, Fumiaki
    Kikugawa, Rina
    Hasegawa, Fumi
    Tsujinaka, Shingo
    Miyakura, Yasuyuki
    Noda, Hiroshi
    Konishi, Fumio
    Rikiyama, Toshiki
    CANCER SCIENCE, 2018, 109 : 458 - 458
12345